Oxurion is a biotechnology company focused on developing innovative treatments for vitreo-retinal diseases, with a strong focus on diabetic eye disease. The company’s development pipeline currently holds 4 drug candidates (THR-409, THR-317, THR-687, THR-149) targeting selective or all key segments of the diabetic eye disease market: diabetic retinopathy (DR), with or without diabetic macular edema.(DME).
Oxurion pioneered the new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in over 50 countries worldwide. In the US, ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics Inc. Novartis commercializes JETREA® outside the US.
Oxurion (formerly known as ThromboGenics) is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol OXUR.